A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 03 Nov 2017
At a glance
- Drugs Ivacaftor (Primary) ; Lumacaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Registrational
- Sponsors Vertex Pharmaceuticals
- 03 Nov 2017 According to a Vertex Pharmaceuticals media release, interim data were presented at the Annual North American Cystic Fibrosis Conference (NACFC), November 2 to 4, 2017.
- 03 Nov 2017 Interim data presented in a Vertex Pharmaceuticals Media Release.
- 09 Aug 2017 Planned number of patients changed from 245 to 240.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History